Table 3.
a Univariate analysis of factors affecting OS, RFS, and GRFS. b Univariate analysis of factors affecting NRM and relapse.
| Variable | OS | RFS | GRFS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | CI | P-value | HR | CI | P-value | HR | CI | P-value | |
| a | |||||||||
| Age at BMT per 10-year increase | 1.27 | 0.70–2.33 | 0.44 | 0.90 | 0.55–1.48 | 0.68 | 0.96 | 0.63–1.46 | 0.86 |
| Year of BMT per 1-year increase | 1.15 | 0.87–1.50 | 0.32 | 0.94 | 0.78–1.13 | 0.51 | 1.06 | 0.89–1.25 | 0.52 |
| Gender (men vs women) | 0.66 | 0.27–1.60 | 0.36 | 0.82 | 0.39–1.73 | 0.61 | 0.84 | 0.45–1.58 | 0.59 |
| HCT-CI (≥3 vs <3) N = 64 | 3.97 | 1.51–10.4 | 0.005 | 2.16 | 1.04–4.52 | 0.040 | 1.48 | 0.78–2.79 | 0.23 |
| High risk cytogenetics (yes vs no) N = 66 | 1.02 | 0.30–3.50 | 0.97 | 1.31 | 0.50–3.47 | 0.58 | 1.52 | 0.67–3.48 | 0.32 |
| JAK2 mutated (yes vs no) N = 66 | 1.35 | 0.49–3.75 | 0.57 | 1.01 | 0.44–2.32 | 0.99 | 0.58 | 0.30–1.14 | 0.11 |
| CALR mutated (yes vs no) N = 64 | 1.00 | 0.29–3.44 | 0.99 | 1.56 | 0.58–4.22 | 0.38 | 1.00 | 0.41–2.42 | 0.99 |
| MPL mutated (yes vs no) N = 64 | 0.74 | 0.10–5.60 | 0.77 | 1.06 | 0.25–4.48 | 0.94 | 2.53 | 0.88–7.31 | 0.09 |
| Prior JAK inhibitor use (yes vs no) N = 68 | 2.82 | 0.38–21.1 | 0.31 | 2.07 | 0.49–8.73 | 0.32 | 2.10 | 0.65–6.81 | 0.22 |
| HMA+/− JAKi vs JAKi alone N = 54 | 1.69 | 0.58–4.90 | 0.33 | 1.69 | 0.66–4.35 | 0.28 | 1.41 | 0.66–3.04 | 0.38 |
| Spleen size at BMT (≥22 vs <22 cm) N = 62 | 0.71 | 0.20–2.58 | 0.62 | 1.40 | 0.58–3.39 | 0.45 | 0.69 | 0.30–1.59 | 0.38 |
| Spleen size at BMT (≥22 + prior splenectomy vs <22 cm) N = 67 | 1.01 | 0.38–2.67 | 0.99 | 1.52 | 0.69–3.32 | 0.30 | 0.85 | 0.42–1.70 | 0.64 |
| DIPSS plus at BMT (high vs <high) | 0.87 | 0.32–2.40 | 0.79 | 0.72 | 0.31–1.69 | 0.45 | 0.58 | 0.27–1.21 | 0.14 |
| Donor gender (men vs women) | 0.42 | 0.17–1.00 | 0.05 | 0.48 | 0.22–1.02 | 0.06 | 0.59 | 0.31–1.11 | 0.10 |
| Conditioning regimen MAC vs NMA vs RIC | P = 0.22; log-rank test | P = 0.32; log-rank test | P = 0.31; log-rank test | ||||||
| Graft source (BM vs PB) | 0.22 | 0.03–1.67 | 0.14 | 1.07 | 0.41–2.83 | 0.89 | 0.57 | 0.22–1.47 | 0.25 |
| CD34+ cell dose, ×106/kg (>6 vs ≤6) | 0.67 | 0.27–1.64 | 0.38 | 0.82 | 0.39–1.71 | 0.59 | 1.09 | 0.59–2.01 | 0.79 |
| Recipient CMV (positive vs negative) | 0.71 | 0.30–1.72 | 0.45 | 0.46 | 0.22–0.96 | 0.038 | 0.52 | 0.28–0.97 | 0.039 |
| Variable | NRM | Relapse | ||||
|---|---|---|---|---|---|---|
| HR | CI | P-value | HR | CI | P-value | |
| b | ||||||
| Age at BMT per 10-year increase | 1.88 | 1.08–3.26 | 0.025 | 0.36 | 0.16–0.81 | 0.014 |
| Year of BMT per 1-year increase | 1.13 | 0.84–1.52 | 0.40 | 0.73 | 0.61–0.87 | <0.001 |
| Gender (men vs women) | 0.65 | 0.24–1.76 | 0.39 | 1.56 | 0.51–4.79 | 0.44 |
| HCT-CI (≥3 vs <3) N = 64 | 4.07 | 1.32–12.5 | 0.014 | 0.54 | 0.17–1.76 | 0.31 |
| High risk cytogenetics (yes vs no) N = 66 | 0.78 | 0.20–3.09 | 0.73 | 1.24 | 0.30–5.08 | 0.77 |
| JAK2 mutated (yes vs no) N = 66 | 1.21 | 0.39–3.79 | 0.74 | 0.70 | 0.22–2.25 | 0.55 |
| CALR mutated (yes vs no) N = 64 | 0.91 | 0.20–4.12 | 0.90 | 2.80 | 0.85–9.25 | 0.09 |
| MPL mutated (yes vs no) N = 64 | 1.11 | 0.17–7.35 | 0.91 | 1.13 | 0.13–9.86 | 0.91 |
| Prior JAK inhibitor use (yes vs no) N = 68 | 2.08 | 0.25–17.5 | 0.50 | 1.55 | 0.19–12.5 | 0.68 |
| HMA+/− JAKi vs JAKi alone (N = 54) | 2.33 | 0.78–7.02 | 0.13 | 0.48 | 0.06–3.85 | 0.49 |
| Spleen size at BMT (≥22 vs <22 cm) N = 62 | 0.57 | 0.12–2.73 | 0.48 | 4.57 | 1.31–16.0 | 0.017 |
| Spleen size at BMT (≥22 + prior splenectomy vs <22 cm) N = 67 | 0.40 | 0.08–1.89 | 0.25 | 6.37 | 2.02–20.1 | 0.002 |
| DIPSS plus at BMT (high vs <high) | 1.01 | 0.33–3.07 | 0.99 | 0.64 | 0.19–2.14 | 0.47 |
| Donor gender (men vs women) | 0.40 | 0.15–1.08 | 0.07 | 1.39 | 0.40–4.86 | 0.61 |
| Conditioning regimen MAC vs NMA vs RIC | P = 0.51; Gray test | P = 0.57; Gray test | ||||
| Graft source (BM vs PB) | P = 0.08; Gray test | 4.92 | 1.68–14.4 | 0.004 | ||
| CD34+ cell dose, ×106/kg (>6 vs ≤6) | 0.70 | 0.25–1.96 | 0.49 | 1.43 | 0.49–4.15 | 0.51 |
| Recipient CMV (positive vs negative) | 0.87 | 0.31–2.42 | 0.79 | 0.32 | 0.11–0.94 | 0.038 |
BM bone marrow, BMT blood or marrow transplantation, CI 95% confidence intervals, CMV cytomegalovirus, DIPSS Dynamic International Prognostic Scoring System, GRFS GVHD-free relapse-free survival, GVHD graft versus host disease, HCT-CI Hematopoietic Cell Transplantation-specific Comorbidity Index, JAK Janus kinase, NMA non-myeloablative conditioning, NRM non-relapse mortality, OS overall survival, PB peripheral blood, RFS relapse free survival, RIC reduced-intensity conditioning.
Statistically significant values have been highlighted as bold.